Format

Send to

Choose Destination
Pharmacogenomics. 2017 Oct;18(15):1413-1425. doi: 10.2217/pgs-2017-0073. Epub 2017 Oct 4.

The pharmacogenomics of severe traumatic brain injury.

Adams SM1,2, Conley YP3,4, Wagner AK5,6, Jha RM2,6,7,8,9, Clark RS6,7,10,11, Poloyac SM1,2,6, Kochanek PM2,6,7, Empey PE2,6,12.

Author information

1
Department of Pharmaceutical Sciences, Center for Clinical Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA.
2
Clinical & Translational Science Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA.
3
Health Promotion & Development, School of Nursing, University of Pittsburgh, Pittsburgh, PA 15261, USA.
4
Department of Human Genetics, School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA.
5
Department of Physical Medicine & Rehabilitation, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA.
6
Safar Center for Resuscitation Research, University of Pittsburgh, Pittsburgh, PA 15224, USA.
7
Department of Critical Care Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA.
8
Department of Neurology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA.
9
Department of Neurological Surgery, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA.
10
Department of Pediatrics, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA.
11
Division of Pediatric Critical Care Medicine, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA 15224, USA.
12
Department of Pharmacy & Therapeutics, Center for Clinical Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA.

Abstract

Pharmacotherapy for traumatic brain injury (TBI) is focused on resuscitation, prevention of secondary injury, rehabilitation and recovery. Pharmacogenomics may play a role in TBI for predicting therapies for sedation, analgesia, seizure prevention, intracranial pressure-directed therapy and neurobehavioral/psychiatric symptoms. Research into genetic predictors of outcomes and susceptibility to complications may also help clinicians to tailor therapeutics for high-risk individuals. Additionally, the expanding use of genomics in the drug development pipeline has provided insight to novel investigational and repurposed medications that may be useful in the treatment of TBI and its complications. Genomics in the context of treatment and prognostication for patients with TBI is a promising area for clinical progress of pharmacogenomics.

KEYWORDS:

biomarkers; drug development; neurocritical care; pharmacogenomics; pharmacokinetics; prognostication; therapy; transporters; traumatic brain injury

PMID:
28975867
PMCID:
PMC5694019
DOI:
10.2217/pgs-2017-0073
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center